OBJECTIVE: Protein kinase Cδ (PKCδ) activation has been shown to be a principal rate-limiting step in matrix-degrading enzyme production in human articular chondrocytes. The aim of this study was to assess the role of the PKC pathways, specifically PKCδ, in intervertebral disc tissue homeostasis. METHODS: Using in vitro, ex vivo, and in vivo techniques, we evaluated the pathophysiologic role of the PKCδ pathway by examining 1) proteoglycan deposition, 2) matrix-degrading enzyme production and activity, 3) downstream signaling pathways regulated by PKCδ, and 4) the effect on in vivo models of disc degeneration in genetically engineered PKCδ-knockout mice. RESULTS: Studies of pathway-specific inhibitors revealed a vital role of the PKCδ/MAPK (ERK, p38, JNK) axis and NF-κB in disc homeostasis. Accordingly, in an in vivo model of disc injury, PKCδ-knockout mice were markedly resistant to disc degeneration. CONCLUSION: Suppression of the PKCδ pathway may be beneficial in the prevention and/or treatment of disc degeneration. The results of this study provide evidence for a potential therapeutic role of pathway-specific inhibitors of the PKCδ cascade in the future.
OBJECTIVE: Protein kinase Cδ (PKCδ) activation has been shown to be a principal rate-limiting step in matrix-degrading enzyme production in human articular chondrocytes. The aim of this study was to assess the role of the PKC pathways, specifically PKCδ, in intervertebral disc tissue homeostasis. METHODS: Using in vitro, ex vivo, and in vivo techniques, we evaluated the pathophysiologic role of the PKCδ pathway by examining 1) proteoglycan deposition, 2) matrix-degrading enzyme production and activity, 3) downstream signaling pathways regulated by PKCδ, and 4) the effect on in vivo models of disc degeneration in genetically engineered PKCδ-knockout mice. RESULTS: Studies of pathway-specific inhibitors revealed a vital role of the PKCδ/MAPK (ERK, p38, JNK) axis and NF-κB in disc homeostasis. Accordingly, in an in vivo model of disc injury, PKCδ-knockout mice were markedly resistant to disc degeneration. CONCLUSION: Suppression of the PKCδ pathway may be beneficial in the prevention and/or treatment of disc degeneration. The results of this study provide evidence for a potential therapeutic role of pathway-specific inhibitors of the PKCδ cascade in the future.
Authors: Howard An; Scott D Boden; James Kang; Harvinder S Sandhu; William Abdu; James Weinstein Journal: Spine (Phila Pa 1976) Date: 2003-08-01 Impact factor: 3.468
Authors: Gary J Litherland; Martina S Elias; Wang Hui; Christopher D Macdonald; Jonathon B Catterall; Matt J Barter; Matthew J Farren; Matthew Jefferson; Andrew D Rowan Journal: J Biol Chem Date: 2010-05-12 Impact factor: 5.157
Authors: Xin Li; Frank M Phillips; Howard S An; Michael Ellman; Eugene J Thonar; William Wu; Daniel Park; Hee-Jeong Im Journal: Spine (Phila Pa 1976) Date: 2008-11-15 Impact factor: 3.468
Authors: Xin Li; Howard S An; Michael Ellman; Frank Phillips; Eugene J Thonar; Daniel K Park; Ranjith K Udayakumar; Hee-Jeong Im Journal: Arthritis Res Ther Date: 2008-04-24 Impact factor: 5.156
Authors: Andrew S Lee; Michael B Ellman; Dongyao Yan; Jeffrey S Kroin; Brian J Cole; Andre J van Wijnen; Hee-Jeong Im Journal: Gene Date: 2013-07-02 Impact factor: 3.688
Authors: Jae-Sung Kim; Kasra Ahmadinia; Xin Li; John L Hamilton; Steven Andrews; Chris A Haralampus; Guozhi Xiao; Hong-Moon Sohn; Jae-Won You; Yo-Seob Seo; Gary S Stein; Andre J Van Wijnen; Su-Gwan Kim; Hee-Jeong Im Journal: J Cell Physiol Date: 2015-11 Impact factor: 6.384
Authors: Jae-Sung Kim; Michael B Ellman; Dongyao Yan; Howard S An; Ranjan Kc; Xin Li; Di Chen; Guozhi Xiao; Gabriella Cs-Szabo; David W Hoskin; Doug D Buechter; Andre J Van Wijnen; Hee-Jeong Im Journal: J Cell Physiol Date: 2013-09 Impact factor: 6.384
Authors: Ranjan Kc; Xin Li; Robin M Voigt; Michael B Ellman; Keith C Summa; Martha Hotz Vitaterna; Ali Keshavarizian; Fred W Turek; Qing-Jun Meng; Gary S Stein; Andre J van Wijnen; Di Chen; Christopher B Forsyth; Hee-Jeong Im Journal: J Cell Physiol Date: 2015-09 Impact factor: 6.384